Table 5.

Cox proportional hazards—main effects for ε4 carrier status. Outcome: MCI

Predictor variables	Main effects (unadjusted) hazard ratio (95% CI)	Main effects adjusteda hazard ratio (95% CI)	Main effects adjustedb hazard ratio (95% CI)
ε4 carrier	1.17 (1.04–1.32)*	1.37 (1.22–1.55)**	1.37 (1.22–1.55)**
Use of an anxiolytic	1.17 (.821–1.67)	1.36 (.949–1.96)	1.29 (.901–1.86)
Did not use anxiolytic	1.19 (1.04–1.35)*	1.39 (1.22–1.58)**	1.36 (1.20–1.55)**
- Alprazolam	1.34 (.572–3.15)	1.69 (.648–4.39)	1.59 (.604–4.19)
- No Alprazolam use	1.18 (1.05–1.33)*	1.38 (1.22–1.57)**	1.38 (1.22–1.56)**
- Clonazapam use	2.01 (.788–5.15)	2.62 (.966–7.10)	2.02 (.688–5.91)
- No Clonazapam use	1.17 (1.04–1.32)*	1.38 (1.22–1.56)**	1.37 (1.21–1.55)**
- Lorazapam use	1.17 (.549–2.52)	1.17 (.514–2.68)	1.17 (.512–2.69)
- No Lorazapam use	1.18 (1.05–1.34)*	1.39 (1.21–1.57)**	1.38 (1.22–1.56)**
- Paroxetine use	.964 (.351–2.65)	1.09 (.391–3.03)	1.07 (.383–2.98)
- No Paroxetine use	1.19 (1.05–1.34)*	1.40 (1.24–1.58)**	1.39 (1.23–1.57)**
- Venlafaxine use	.344 (.078–1.53)	.358 (.068–1.88)	.215 (.039–1.19)
- No Venlafaxine use	1.20 (1.06–1.35)*	1.40 (1.24–1.58)**	1.39 (1.23–1.58)**

^aAdjusted for sex, age, education, race, and Hispanic origin.

^bAdjusted for sex, age, education, race, Hispanic origin, and AD medication use.

^*Indicates statistical significance at p <.05.

^**Indicates p <0.001.